Integra LifeSciences Holdings Corporation (IART)
Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Integra (IART) is Poised to Beat Earnings Estimates Again
Integra (IART) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra Q4 Earnings & Revenues Beat Estimates, Margins Down, Stock Up
IART tops Q4 EPS and revenue estimates despite margin pressure and a sales dip, as shares edge higher and 2026 guidance signals modest growth.
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q4 2025 Earnings Call Transcript
Integra (IART) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation ( IART ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christopher Ward - Senior Director of Investor Relations Mojdeh Poul - President, CEO & Director Lea Knight - Executive VP & CFO Conference Call Participants Vikramjeet Chopra - Wells Fargo Securities, LLC, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Presentation Operator Good day, and welcome to the Integra LifeSciences Third Quarter 2025 Financial Results. [Operator Instructions] As a reminder, this call may be recorded.
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Integra LifeSciences (IART) Q3 Earnings Beat Estimates
Integra LifeSciences (IART) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.41 per share a year ago.
Integra LifeSciences Still Recovering From Self-Inflicted Wounds
Integra LifeSciences remains deeply discounted due to ongoing operational setbacks, with the market adopting a cautious 'show me' stance until clear improvements emerge. Remediation and margin improvement plans are underway, but shipping holds and tariffs continue to pressure revenue and profitability, delaying a full recovery until at least 2026. Core businesses, including higher-value wound care products, have shown resilience, and long-term growth drivers remain intact, supporting potential upside for patient investors.
